Bococizumab: SPIRE clinical trial programme (terminated)
Pfizer announced on Tuesday, 1st November 2016 that it was discontinuing development of bococizumab, its PCSK9 inhibitor. According to the press release, the Company stated that: 'The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide value to patients, physicians, or shareholders. As a result, Pfizer has decided to discontinue the development program, including the two ongoing cardiovascular outcome studies.
Press release: Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor.